DPP-4 inhibitors and GLP-1 analogues are widely used to treat people with type 2 diabetes. People with moderately elevated blood glucose are said to be at an increased risk for developing type 2 ...

The Saudi Arabia diabetes market reached a value of USD 373.4 million in 2024 and is projected to grow to USD 494.4 million by 2033, exhibiting a steady compound annual growth rate (CAGR) of 3.17% ...

Indian pharma speeds up access to global therapies while targeting treatment gaps: Nandita Vijayasimha, Bengaluru Saturday, June 28, 2025, 08:00 Hrs [IST] Indian pharma is now agg ...

Dapiglutide, a novel GLP-1/GLP-2 receptor agonist, was associated with body weight reductions of up to 8.3% at 13 weeks for ...

CVS Caremark will stop covering Eli Lilly’s Zepbound. Wegovy, the GLP-1 medication to treat obesity from Lilly competitor ...

Though much of the dust has settled around Novo Nordisk and Eli Lilly’s crusade against compounded GLP-1s, the recent ...

According to the CDC, 1 in 5 American adults is living with obesity. In recent years, many have turned to weight loss drugs ...

She began using Wegovy, the version of Ozempic approved for weight loss, after struggling with obesity. She reveals which ...

Altimmune’s pemvidutide failed to significantly improve fibrosis in MASH patients in a Phase IIb study. The biotech crashed ...

GLP-1RA use initially lowered delirium risk but eventually heightened delirium risk after 5 years among patients with type 2 diabetes.

Novo Nordisk's GLP-1 receptor agonist semaglutide has been shown to help people struggling with alcohol use disorder (AUD) reduce the amount they drink – pointing to yet another potential use ...

"It's criminal to put someone on a GLP-1 and not put them on a dietary plan," says Phil Vella, founder of Vita Bella Clinics, ...